AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Bank of America Securities Keeps Hold Rating on Arcus Biosciences with $12 Price Target
ByAinvest
Tuesday, Aug 26, 2025 9:48 am ET1min read
Bank of America Securities analyst Jason Zemansky reiterated a Hold rating on Arcus Biosciences with a $12.00 price target. Arcus Biosciences has a Strong Buy analyst consensus rating with a $28.86 average price target, representing a 174.07% upside. The company has a market cap of $1.12B and a P/E ratio of -3.32.
Arcus Biosciences (NYSE: RCUS), a clinical-stage biopharmaceutical company, has announced its participation in three upcoming investor conferences in September 2025. The company will be represented by its management team at the following events:1. Citi’s 2025 Biotech Back to School Conference
- Date: Wednesday, September 3rd, 2025
- Location: Boston, MA
- Format: Fireside chat & 1x1 meetings
- Time: 11:15 a.m. ET
2. H.C. Wainwright 27th Annual Global Investment Conference
- Date: Tuesday, September 9th, 2025
- Location: New York, NY
- Format: Fireside chat & 1x1 meetings
- Time: 8:00 a.m. ET
3. Morgan Stanley 23rd Annual Global Healthcare Conference
- Date: Wednesday, September 10th, 2025
- Location: New York, NY
- Format: Fireside chat & 1x1 meetings
- Time: 8:30 a.m. ET
Live webcasts of the fireside chats will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. Replays will be available following the live event.
Analyst ratings and market metrics for Arcus Biosciences highlight a mixed outlook. Bank of America Securities analyst Jason Zemansky reiterated a Hold rating on the company with a $12.00 price target. In contrast, Arcus Biosciences has a Strong Buy analyst consensus rating with an average price target of $28.86, representing a 174.07% upside. The company has a market cap of $1.12 billion and a P/E ratio of -3.32.
Arcus Biosciences focuses on developing differentiated molecules and combination therapies for patients with cancer. The company's pipeline includes domvanalimab, an Fc-silent anti-TIGIT antibody in combination with zimberelimab, an anti-PD-1 antibody, for upper gastrointestinal and non-small cell lung cancer; casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma; and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer [1].
References:
[1] https://www.biospace.com/press-releases/arcus-biosciences-to-participate-in-three-upcoming-september-2025-investor-conferences
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet